Androgenetic Alopecia Drug Development Gains Momentum as 80+ Companies Advance Next-Generation Therapies, estimates DelveInsight

DelveInsight's "Androgenetic Alopecia Pipeline Insight 2025" report presents a thorough and strategic assessment of the current research and development landscape. The study analyzes clinical trial advancements, novel therapies, mechanisms of action, competitive dynamics, and major initiatives undertaken by key players. The Androgenetic alopecia pipeline report delivers detailed insights into 12+ companies and 12+ pipeline candidates actively shaping the Androgenetic alopecia drug development ecosystem.

As Androgenetic alopecia continues to rise worldwide and increasingly contributes to comorbidities such as diabetes, cardiovascular disorders, and certain cancers, the demand for safer and more effective therapeutic solutions is steadily growing.

According to DelveInsight, the Androgenetic alopecia pipeline includes 80+ pharmaceutical and biotechnology companies developing 100+ therapeutic candidates aimed at treating the condition. These assets span multiple clinical and preclinical stages, highlighting robust innovation efforts and sustained commitment toward addressing one of today's most widespread public health concerns.

Explore the advanced Androgenetic alopecia drug development landscape here:
https://www.delveinsight.com/report-store/androgenetic-alopecia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Highlights from the Androgenetic Alopecia Pipeline Report

• DelveInsight's Androgenetic alopecia pipeline analysis highlights a dynamic environment with 12+ active companies working on 12+ pipeline therapies for the treatment of Androgenetic alopecia.

• Androgenetic alopecia, widely recognized as pattern hair loss, is currently managed primarily with two FDA-approved treatments-topical minoxidil and oral finasteride. Although these therapies remain the standard of care, increasing attention has been directed toward topical finasteride due to its potential to minimize systemic adverse effects. Despite encouraging outcomes, topical finasteride remains off-label and had not received FDA approval as of 2024.

• Leading Androgenetic alopecia companies including Kerastem, Addpharma, Cutia Therapeutics, Biosplice Therapeutics, Aclaris Therapeutics, Kintor Pharmaceutical, Dong-A ST Co., Ltd., Cassiopea, Follica, Applied Biology, Inc., AndroScience Corporation, AnnJi Pharmaceutical, Carmell Therapeutics, and others are actively investigating novel therapies to enhance the treatment landscape.

• Noteworthy pipeline candidates progressing through various development stages include KX-826, Clascoterone, and additional emerging therapies.

• In October 2025, Pelage Pharmaceuticals-a clinical-stage regenerative medicine biotechnology firm-announced the successful completion of a USD 120 million Series B funding round, co-led by ARCH Venture Partners and GV (Google Ventures), with participation from Main Street Advisors, Visionary Ventures, and YK Bioventures. The funding will support the continued development of PP405, a topical small-molecule therapy designed to reactivate dormant hair follicle stem cells, representing a potential first-in-class treatment for both male and female hair loss.

• In May 2025, Veradermics, Inc. released results from a randomized, double-blind, placebo-controlled, parallel-group, multi-dose study evaluating the safety and efficacy of VDPHL01 in male patients with Androgenetic alopecia.

• In April 2025, Chong Kun Dang Pharmaceutical reported outcomes from a randomized, double-blind, multicenter, placebo-controlled, parallel-group Phase III trial assessing the efficacy and safety of CKD-843 in male Androgenetic alopecia patients.

• Also in April 2025, AnHorn Medicines Co., Ltd. announced findings from a randomized, double-blind, placebo-controlled, parallel-group, dose-escalation study evaluating the safety, tolerability, and pharmacokinetics of AH-001 following single and multiple ascending topical doses.

• In February 2025, Pelage Pharmaceuticals, Inc. disclosed results from a randomized, multicenter, double-blind, vehicle-controlled Phase IIa study assessing the safety, pharmacokinetics, and efficacy of PP405 in adults with Androgenetic alopecia.

• In December 2024, Applied Biology, Inc. announced clinical study results evaluating DA-002 and DA-005 as potential treatments for hair loss.

• In August 2024, Pelage Pharmaceuticals initiated its Phase IIa clinical trial, dosing the first patients. The study is designed to evaluate the safety and effectiveness of PP405, a novel topical therapy intended to stimulate hair growth by reactivating dormant hair follicle stem cells. The trial plans to enroll 60 male and female participants.

• In January 2024, Sol-Gel Technologies, Ltd. announced FDA approval of its first proprietary drug, TWYNEO® (tretinoin/benzoyl peroxide) cream 0.1%/3%, indicated for the treatment of Androgenetic alopecia in adults and pediatric patients aged nine years and above. TWYNEO leverages Sol-Gel's proprietary encapsulation technology to enhance stability, controlled release, safety, and therapeutic efficacy.

Androgenetic Alopecia Overview

Androgenetic alopecia is a common form of hair loss affecting both men and women. In males, it is often referred to as male-pattern baldness and typically follows a characteristic pattern, beginning at the temples and progressing to an "M-shaped" hairline. The condition is genetically inherited and driven by increased androgen sensitivity, impacting up to 50% of individuals of both sexes. Hair thinning generally begins after puberty and follows distinct gender-specific patterns-men experience hair loss primarily at the crown and frontotemporal regions, while women usually retain the frontal hairline but develop diffuse thinning over the crown. Elevated levels of dihydrotestosterone, increased 5-alpha reductase activity, and a higher density of androgen receptors in affected scalp areas are commonly observed. Diagnosis is typically based on clinical presentation and family history. Currently, two FDA-approved therapies-topical minoxidil and oral finasteride-are available, both requiring long-term, continuous use to maintain therapeutic benefits.

Download the Androgenetic alopecia sample report for detailed treatment insights:
https://www.delveinsight.com/sample-request/androgenetic-alopecia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Emerging Androgenetic Alopecia Therapies by Development Stage

• KX-826 - Kintor Pharmaceutical
• Clascoterone - Cassiopea

Androgenetic Alopecia Pipeline Analysis by Route of Administration

The Androgenetic alopecia pipeline report evaluates therapies based on routes of administration, including:
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Androgenetic Alopecia Pipeline by Molecule Type
Pipeline products are categorized by molecular class, including:
• Monoclonal antibodies
• Peptides
• Polymers
• Small molecules
• Gene therapies

Therapeutic Assessment Covered in the Report

• Assessment by product type
• Analysis by development stage and product category
• Evaluation by route of administration
• Stage-wise and route-specific assessment
• Molecule-based analysis
• Stage-wise molecule classification

DelveInsight's Androgenetic alopecia pipeline report analyzes 20+ products across multiple stages of development, including:
• Late-stage (Phase III)
• Mid-stage (Phase II)
• Early-stage (Phase I)
• Preclinical and discovery-stage candidates
• Discontinued and inactive programs

Additional in-depth product profiles are included in the report. Download the Androgenetic alopecia pipeline report to explore emerging therapies:
https://www.delveinsight.com/sample-request/hepatitis-c-virus-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Companies in the Androgenetic Alopecia Therapeutics Market
Major companies advancing Androgenetic alopecia therapies include Kerastem, Addpharma, Cutia Therapeutics, Biosplice Therapeutics, Aclaris Therapeutics (NASDAQ: ACRS), Kintor Pharmaceutical (HKEX: 9939), Dong-A ST Co., Ltd. (KRX: 170900), Cassiopea (SWX: SKIN), Follica, Applied Biology, Inc., AndroScience Corporation, AnnJi Pharmaceutical (TPEx: 6477), Carmell Therapeutics, and others.

Androgenetic Alopecia Pipeline Analysis Insights
The report provides:
• Detailed profiles of companies developing Androgenetic alopecia therapies, including asset counts by company
• Classification of candidates into early, mid, and late development stages
• Analysis of targeted therapy development, including active and discontinued programs
• Segmentation of pipeline assets by development stage, route of administration, molecular type, mechanism of action, and monotherapy or combination approach
• Comprehensive coverage of collaborations, licensing agreements, and funding activities supporting future market growth

The analysis is based on data sourced from proprietary databases, company and academic websites, clinical trial registries, scientific conferences, SEC filings, investor presentations, and industry-specific publications.

Access in-depth insights into emerging Androgenetic alopecia therapies and strategic developments here:
https://www.delveinsight.com/report-store/androgenetic-alopecia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.